Efficacy and safety of topical ruxolitinib cream for the treatment of vitiligo: A systematic review and meta-analysis of randomized controlled trials

Affiliations

¹ Department of Dermatology, King Edward Medical University, Lahore, Pakistan.
² Department of Medicine, King Edward Medical University, Lahore, Pakistan.
³ Department of Internal Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
⁴ Department of Internal Medicine, Limerick University Hospital, Limerick, Ireland.
⁵ Hamad Medical Corporation, Doha, Qatar.

Meta-Analysis

Muhammad Ehsan et al. J Cosmet Dermatol. 2024 Jan.

. 2024 Jan;23(1):350-353.

doi: 10.1111/jocd.15921. Epub 2023 Jul 5.

¹ Department of Dermatology, King Edward Medical University, Lahore, Pakistan.
² Department of Medicine, King Edward Medical University, Lahore, Pakistan.
³ Department of Internal Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
⁴ Department of Internal Medicine, Limerick University Hospital, Limerick, Ireland.
⁵ Hamad Medical Corporation, Doha, Qatar.

No abstract available

Keywords: F-VASI50; F-VASI75; meta-analysis; ruxolitinib; vitiligo.

References

1. Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571-592. doi:10.1159/000506103
1. Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110-120. doi:10.1016/S0140-6736(20)30609-7
1. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
1. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
1. Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445-1455. doi:10.1056/NEJMoa2118828